Liminal BioSciences buys Fairhaven, secures VC investment

Liminal BioSciences, a Laval, Quebec-based clinical-stage biopharmaceutical company, has acquired Fairhaven Pharmaceuticals, a developer of small molecule, oral therapeutics for severe inflammatory conditions, for C$8 million in shares.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this